Royalty Pharma declares third quarter 2026 dividend
NEW YORK, NY, July 17, 2026 — The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
19
Development-stage therapies
16
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$3.3bn
Portfolio Receipts
(2025)
(2025)
$3.0bn
Adjusted EBITDA
(2025)
(2025)
$2.5bn
Average annual capital deployed (2020-2025)
$4.7bn
Announced value of transactions (2025)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q1 2026
Corporate presentation
Latest releases
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
NEW YORK, NY, July 15, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
NEW YORK, NY, June 4, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.
Royalty Pharma to present at upcoming investor conferences
NEW YORK, NY, May 7, 2026 — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May
